SCHEMBL2196576

SCHEMBL2196576

Nc1ccc(O)nc1Nc1ccccc1C1CC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.35
KHK P50053 1/20 0.34
BRAF P15056 1/20 0.33
IGF1R P08069 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
CDK7 P50613 1/20 0.31
CDK9 P50750 1/20 0.31
SRC P12931 1/20 0.31
RIPK1 Q13546 1/20 0.31
KDM4E B2RXH2 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
AURKA O14965 1/20 0.30
HDAC3 O15379 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC2 Q92769 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194787 0.78 IGF1R (0.38) HSD17B10IGF1RGAAMAPTMEN1
SCHEMBL2193744 0.76 PDE5A (0.46) HSD17B10IGF1RKDM4EMAPTMEN1
SCHEMBL2192476 0.76 MAPT (0.44) KDM4EMAPTMEN1KMT2AAURKA
SCHEMBL2196525 0.75 EPHX2 (0.48) HSD17B10KDM4EGAAMAPTMEN1
SCHEMBL2193574 0.74 KHK (0.39) HSD17B10KHKBRAFMAPTMEN1
SCHEMBL2195557 0.72 EPHX2 (0.46) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL29196044 0.72 HSD17B10 (0.46) HSD17B10KHKRIPK1
SCHEMBL2192677 0.71 EGFR (0.38) BRAFKDM4EGAAMAPTMEN1
SCHEMBL2191767 0.71 NUDT1 (0.47) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL2192393 0.69 HTT (0.39) KHKBRAFCDK7CDK9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 HSD17B10 1203/4885KHK 2055/4885BRAF 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.